Literature DB >> 15232613

Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.

Philipp Beckhove1, Markus Feuerer, Mathias Dolenc, Florian Schuetz, Carmen Choi, Nora Sommerfeldt, Jochen Schwendemann, Katrin Ehlert, Peter Altevogt, Gunther Bastert, Volker Schirrmacher, Viktor Umansky.   

Abstract

Bone marrow of breast cancer patients was found to contain CD8(+) T cells specific for peptides derived from breast cancer-associated proteins MUC1 and Her-2/neu. Most of these cells had a central or effector memory phenotype (CD45RA(-)CD62L(+) or CD45RA(-)CD62L(-), respectively). To test their in vivo function, we separated bone marrow-derived CD45RA(+) naive or CD45RA(-)CD45RO(+) memory T cells, stimulated them with autologous dendritic cells pulsed with tumor lysate, and transferred them into NOD/SCID mice bearing autologous breast tumors and normal skin transplants. CD45RA(-) memory but not CD45RA(+) naive T cells infiltrated autologous tumor but not skin tissues after the transfer. These tumor-infiltrating cells had a central or effector memory phenotype and produced perforin. Many of them expressed the P-selectin glycoprotein ligand 1 and were found around P-selectin(+) tumor endothelium. Tumor infiltration included cluster formation in tumor tissue by memory T cells with cotransferred dendritic cells. It was associated with the induction of tumor cell apoptosis and significant tumor reduction. We thus demonstrate selective homing of memory T cells to human tumors and suggest that tumor rejection is based on the recognition of tumor-associated antigens on tumor cells and dendritic cells by autologous specifically activated central and effector memory T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232613      PMCID: PMC437963          DOI: 10.1172/JCI20278

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

Review 1.  Lymphocyte trafficking and regional immunity.

Authors:  E C Butcher; M Williams; K Youngman; L Rott; M Briskin
Journal:  Adv Immunol       Date:  1999       Impact factor: 3.543

2.  CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs.

Authors:  R Förster; A Schubel; D Breitfeld; E Kremmer; I Renner-Müller; E Wolf; M Lipp
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

3.  Expression of functional selectin ligands on Th cells is differentially regulated by IL-12 and IL-4.

Authors:  Y C Lim; L Henault; A J Wagers; G S Kansas; F W Luscinskas; A H Lichtman
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

4.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

Authors:  I J Diel; M Kaufmann; S D Costa; R Holle; G von Minckwitz; E F Solomayer; S Kaul; G Bastert
Journal:  J Natl Cancer Inst       Date:  1996-11-20       Impact factor: 13.506

Review 5.  On immunological memory.

Authors:  R M Zinkernagel; M F Bachmann; T M Kündig; S Oehen; H Pirchet; H Hengartner
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

6.  IL-12, STAT4-dependent up-regulation of CD4(+) T cell core 2 beta-1,6-n-acetylglucosaminyltransferase, an enzyme essential for biosynthesis of P-selectin ligands.

Authors:  Y C Lim; H Xie; C E Come; S I Alexander; M J Grusby; A H Lichtman; F W Luscinskas
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

7.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.

Authors:  P Brossart; K S Heinrich; G Stuhler; L Behnke; V L Reichardt; S Stevanovic; A Muhm; H G Rammensee; L Kanz; W Brugger
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

8.  Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice.

Authors:  D L Greiner; L D Shultz; J Yates; M C Appel; G Perdrizet; R M Hesselton; I Schweitzer; W G Beamer; K L Shultz; S C Pelsue
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

9.  The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium.

Authors:  S B Fox; G D Turner; K C Gatter; A L Harris
Journal:  J Pathol       Date:  1995-12       Impact factor: 7.996

10.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

Authors:  B Fisk; T L Blevins; J T Wharton; C G Ioannides
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  42 in total

1.  Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ.

Authors:  Moritz Koch; Philipp Beckhove; Jan Op den Winkel; Daniel Autenrieth; Philipp Wagner; Daniel Nummer; Sebastian Specht; Dalibor Antolovic; Luis Galindo; Friedrich H Schmitz-Winnenthal; Volker Schirrmacher; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

2.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

Review 3.  FOXOs in cancer immunity: Knowns and unknowns.

Authors:  Youcai Deng; Fangjie Wang; Tiffany Hughes; Jianhua Yu
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

4.  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.

Authors:  Christoph Reissfelder; Slava Stamova; Christina Gossmann; Marion Braun; Andreas Bonertz; Ute Walliczek; Mario Grimm; Nuh N Rahbari; Moritz Koch; Maral Saadati; Axel Benner; Markus W Büchler; Dirk Jäger; Niels Halama; Khashayarsha Khazaie; Jürgen Weitz; Philipp Beckhove
Journal:  J Clin Invest       Date:  2014-12-22       Impact factor: 14.808

5.  Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer.

Authors:  Seyer Safi; Yoshikane Yamauchi; Anchana Rathinasamy; Slava Stamova; Martin Eichhorn; Arne Warth; Geraldine Rauch; Hendrik Dienemann; Hans Hoffmann; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2017-09-08       Impact factor: 8.110

Review 6.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Authors:  Malarvizhi Durai; Christine Krueger; Zhaohui Ye; Linzhao Cheng; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Immunol Immunother       Date:  2008-06-18       Impact factor: 6.968

8.  CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.

Authors:  Daniel Dubinski; Johannes Wölfer; Martin Hasselblatt; Tilman Schneider-Hohendorf; Ulrich Bogdahn; Walter Stummer; Heinz Wiendl; Oliver M Grauer
Journal:  Neuro Oncol       Date:  2015-11-17       Impact factor: 12.300

9.  Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.

Authors:  Petra Cerkovnik; Barbara Jezersek Novakovic; Vida Stegel; Srdjan Novakovic
Journal:  BMC Immunol       Date:  2010-09-13       Impact factor: 3.615

10.  Targeting the autophagy pathway for cancer chemoprevention.

Authors:  Meredith A Steeves; Frank C Dorsey; John L Cleveland
Journal:  Curr Opin Cell Biol       Date:  2010-01-22       Impact factor: 8.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.